These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 9557932

  • 1. Renal response to the angiotensin II receptor subtype 1 antagonist irbesartan versus enalapril in hypertensive patients.
    Pechère-Bertschi A, Nussberger J, Decosterd L, Armagnac C, Sissmann J, Bouroudian M, Brunner HR, Burnier M.
    J Hypertens; 1998 Mar; 16(3):385-93. PubMed ID: 9557932
    [Abstract] [Full Text] [Related]

  • 2. The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.
    Perico N, Remuzzi A, Sangalli F, Azzollini N, Mister M, Ruggenenti P, Remuzzi G.
    J Am Soc Nephrol; 1998 Dec; 9(12):2308-17. PubMed ID: 9848785
    [Abstract] [Full Text] [Related]

  • 3. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.
    Mimran A, Ruilope L, Kerwin L, Nys M, Owens D, Kassler-Taub K, Osbakken M.
    J Hum Hypertens; 1998 Mar; 12(3):203-8. PubMed ID: 9579771
    [Abstract] [Full Text] [Related]

  • 4. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, de la Sierra A, Martín-Hidalgo A, Marín R, MAPAVEL Investigators (Monitorizacíon Ambulatoria Presión Arterial APROVEL).
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [Abstract] [Full Text] [Related]

  • 5. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
    Lacourcière Y.
    Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232
    [Abstract] [Full Text] [Related]

  • 6. Effects and tolerability of irbesartan versus enalapril in patients with severe hypertension. Irbesartan Multicenter Investigators.
    Larochelle P, Flack JM, Marbury TC, Sareli P, Krieger EM, Reeves RA.
    Am J Cardiol; 1997 Dec 15; 80(12):1613-5. PubMed ID: 9416950
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind comparison of irbesartan and enalapril for treatment of mild to moderate hypertension.
    Chiou KR, Chen CH, Ding PY, Chen YT, Ting CT, Huang JL, Chiang AH, Liu CP, Tseng CJ, Chao CT, Chang MS.
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 May 15; 63(5):368-76. PubMed ID: 10862446
    [Abstract] [Full Text] [Related]

  • 8. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.
    Byyny RL, Merrill DD, Bradstreet TE, Sweet CS.
    Cardiovasc Drugs Ther; 1996 Jul 15; 10(3):313-9. PubMed ID: 8877074
    [Abstract] [Full Text] [Related]

  • 9. Efficacy of SR 47436 (BMS-186295), a non-peptide angiotensin AT1 receptor antagonist in hypertensive rat models.
    Lacour C, Canals F, Galindo G, Cazaubon C, Segondy D, Nisato D.
    Eur J Pharmacol; 1994 Nov 03; 264(3):307-16. PubMed ID: 7698170
    [Abstract] [Full Text] [Related]

  • 10. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
    Kanagawa R, Wada T, Sanada T, Ojima M, Inada Y.
    Jpn J Pharmacol; 1997 Mar 03; 73(3):185-90. PubMed ID: 9127812
    [Abstract] [Full Text] [Related]

  • 11. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
    Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL.
    J Hum Hypertens; 2010 Feb 03; 24(2):93-103. PubMed ID: 19458624
    [Abstract] [Full Text] [Related]

  • 12. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
    Havranek EP, Thomas I, Smith WB, Ponce GA, Bilsker M, Munger MA, Wolf RA.
    J Am Coll Cardiol; 1999 Apr 03; 33(5):1174-81. PubMed ID: 10193713
    [Abstract] [Full Text] [Related]

  • 13. Influence of irbesartan and enalapril on changes of renal function associated with the established phase of l-NAME hypertension.
    Jover B, Herizi A, Casellas D, Mimran A.
    J Hypertens; 2001 Nov 03; 19(11):2039-46. PubMed ID: 11677370
    [Abstract] [Full Text] [Related]

  • 14. Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
    De Rosa ML, de Cristofaro A, Rossi M, Baiano A, Cardace P, Albanese L, Vigorito C.
    J Cardiovasc Pharmacol; 2001 Sep 03; 38(3):482-9. PubMed ID: 11486253
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
    Omboni S, Malacco E, Napoli C, Modesti PA, Manolis A, Parati G, Agabiti-Rosei E, Borghi C.
    Adv Ther; 2017 Apr 03; 34(4):784-798. PubMed ID: 28260186
    [Abstract] [Full Text] [Related]

  • 16. Twenty-four-hour ambulatory blood pressure evaluation of antihypertensive agents.
    Zanchetti A.
    J Hypertens Suppl; 1997 Dec 03; 15(7):S21-5. PubMed ID: 9532517
    [Abstract] [Full Text] [Related]

  • 17. Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide.
    Malmqvist K, Kahan T, Dahl M.
    Am J Hypertens; 2000 May 03; 13(5 Pt 1):504-11. PubMed ID: 10826401
    [Abstract] [Full Text] [Related]

  • 18. Comparative effects of combination drug therapy regimens commencing with either losartan potassium, an angiotensin II receptor antagonist, or enalapril maleate for the treatment of severe hypertension.
    Ruff D, Gazdick LP, Berman R, Goldberg AI, Sweet CS.
    J Hypertens; 1996 Feb 03; 14(2):263-70. PubMed ID: 8728306
    [Abstract] [Full Text] [Related]

  • 19. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
    Himmelmann A, Keinänen-Kiukaanniemi S, Wester A, Redón J, Asmar R, Hedner T, Effect Study Group.
    Blood Press; 2001 Feb 03; 10(1):43-51. PubMed ID: 11332334
    [Abstract] [Full Text] [Related]

  • 20. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P, Andersen S, Rossing K, Jensen BR, Parving HH.
    Kidney Int; 2003 May 03; 63(5):1874-80. PubMed ID: 12675866
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.